Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review

Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review

Immune checkpoint inhibitors (ICIs) demonstrate unique advantages in the treatment of lung cancer and are widely used in the era of immunotherapy. However, ICIs can cause adverse reactions. Hematological toxicities induced by immunotherapy are relatively rare. Agranulocytosis, a rare hematologic adv...

Full description

Bibliographic Details
Main Authors: Yanzhu Qin, Shuaiji Lu, Jingwen Chen, Jing Peng, Jijun Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-06-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
PD-1-immune related adverse effects
sintilimab
agranulocytosis
neutropenia
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1415748/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1415748/full

Similar Items